ASCO 2024: Novartis’ Scemblix outperforms standard of care in CML

2024-05-31
Pharmaceutical Technology
临床结果临床3期ASCO会议上市批准疫苗
ASCO 2024: Novartis’ Scemblix outperforms standard of care in CML
Preview
来源: Pharmaceutical Technology
Novartis’ Scemblix generated $136m in sales in Q1 this year, as per the company’s financials. Image Credit: Taljat David / Shutterstock.
Novartis has released positive data from the Phase III ASC4FIRST trial showing that its tyrosine kinase inhibitor (TKI) therapy Scemblix (asciminib) is more effective than the current standard of care (SoC) therapies as a first-line treatment for Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML).
Recommended Buyer's Guides
ASCO 2024: Novartis’ Scemblix outperforms standard of care in CML
Preview
来源: Pharmaceutical Technology
Buyer's Guide
Leading Guide to Compliance Software for the Pharmaceutical Industry
ASCO 2024: Novartis’ Scemblix outperforms standard of care in CML
Preview
来源: Pharmaceutical Technology
Buyer's Guide
Top Guide for Drug Delivery Systems
The results from the open-label Phase III ASC4FIRST study (NCT04971226) were released in a late-breaking abstract and will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting today. The conference, which started today is taking place in Chicago, US, until 4 June.
The trial met its primary endpoint with the Scemblix arm demonstrating a superior major molecular response (MMR) rate of 67.7% at week 48, compared to a 49% MMR rate with an investigator-selected SoC tyrosine kinase inhibitors (TKIs) such as Pfizer’s Bosulif (bosutinib), Bristol Myers Squibb’s Sprycel (dasatinib) and Novartis’ Gleevec/Glivec (imatinib) and Tasigna (nilotinib). The therapy also showed an MMR rate of 69.3% at 48 weeks, compared to an MMR of 40.2% with Gleevec.
“Scemblix is the first CML treatment to show significantly better efficacy compared to investigator-selected standard-of-care TKIs,” said Dr Tim Hughes, South Australian Health & Medical Research Institute (SAHMRI), in the company announcement accompanying the results.
“When you combine superior response with the excellent safety and tolerability profile of Scemblix, we have a very promising potential frontline option for newly diagnosed patients to support them in achieving their treatment goals.”
See Also:BioNTech and CEPI expand deal to boost Africa’s vaccine capabilities
ASCO 2024: Novartis’ Scemblix outperforms standard of care in CML
Preview
来源: Pharmaceutical Technology
Self-amplifying RNA and vaccine innovation: getting from concept to clinic
ASCO 2024: Novartis’ Scemblix outperforms standard of care in CML
Preview
来源: Pharmaceutical Technology
The Scemblix patient group also observed lower adverse event (AE) rates of 38% for Grade 3 or worse adverse events, compared to the 55% and 44% AE rates in the Gleevec monotherapy and investigator-selected SoC groups, respectively.
Scemblix is a tyrosine kinase inhibitor that blocks a BCR-ABL tyrosine kinase protein found in CML cells and stops cell growth and multiplication. In 2021, it received accelerated approval from the US Food and Drug Administration (FDA) as a third-line therapy for patients with Ph+ CML in the chronic phase.
Novartis plans to submit the data from the trial to the FDA via the agency’s Oncology Center of Excellence Real-Time Oncology Review (RTOR) programme. The company reported $136m in sales for Scemblix in Q1 this year, with GlobalData expecting the therapy to pull in approximately $2.4bn by 2030.
GlobalData is the parent company of Pharmaceutical Technology.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。